Patient characteristics
| Characteristic . | No. (% [frequency]) . |
|---|---|
| Total No. of patients | 250 |
| Sex | |
| Male | 127 (51) |
| Female | 123 (49) |
| Age at first VLDRT, y | |
| Median (IQR) | 67 (57-76) |
| Minimum-maximum | 20-94 |
| Original lymphoma stage | |
| I | 71 (29) |
| II | 30 (12) |
| III | 35 (14) |
| IV | 82 (33) |
| Localized (cutaneous) | 29 (12) |
| Multifocal (cutaneous) | 2 (0.8) |
| Unknown | 1 |
| Bone marrow biopsy at initial diagnosis | |
| Negative | 105 (71) |
| Positive | 42 (29) |
| Unknown | 103 |
| Previous diagnosis of DLBCL or aggressive lymphoma | 25 (10) |
| Exposure to systemic therapy before VLDRT | |
| No. of previous lines of systemic therapy | |
| 0 | 114 (46) |
| 1 | 57 (23) |
| 2-4 | 70 (28) |
| >4 | 9 (3.6) |
| Previous rituximab | 95 (38) |
| Previous chemotherapy or chemoimmunotherapy | 85 (34) |
| No. of previous transplantations | |
| 0 | 245 (98) |
| 1 | 4 (1.6) |
| 2 | 1 (0.4) |
| Characteristic . | No. (% [frequency]) . |
|---|---|
| Total No. of patients | 250 |
| Sex | |
| Male | 127 (51) |
| Female | 123 (49) |
| Age at first VLDRT, y | |
| Median (IQR) | 67 (57-76) |
| Minimum-maximum | 20-94 |
| Original lymphoma stage | |
| I | 71 (29) |
| II | 30 (12) |
| III | 35 (14) |
| IV | 82 (33) |
| Localized (cutaneous) | 29 (12) |
| Multifocal (cutaneous) | 2 (0.8) |
| Unknown | 1 |
| Bone marrow biopsy at initial diagnosis | |
| Negative | 105 (71) |
| Positive | 42 (29) |
| Unknown | 103 |
| Previous diagnosis of DLBCL or aggressive lymphoma | 25 (10) |
| Exposure to systemic therapy before VLDRT | |
| No. of previous lines of systemic therapy | |
| 0 | 114 (46) |
| 1 | 57 (23) |
| 2-4 | 70 (28) |
| >4 | 9 (3.6) |
| Previous rituximab | 95 (38) |
| Previous chemotherapy or chemoimmunotherapy | 85 (34) |
| No. of previous transplantations | |
| 0 | 245 (98) |
| 1 | 4 (1.6) |
| 2 | 1 (0.4) |
IQR, interquartile range.